Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.62 AUD | +2.21% | +0.22% | -4.15% |
Apr. 30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
Apr. 17 | Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant | MT |
Sales 2024 * | 297M 196M | Sales 2025 * | 398M 263M | Capitalization | 478M 316M |
---|---|---|---|---|---|
Net income 2024 * | 21M 13.88M | Net income 2025 * | 30M 19.83M | EV / Sales 2024 * | 1.67 x |
Net Debt 2024 * | 17.01M 11.24M | Net Debt 2025 * | 22.65M 14.97M | EV / Sales 2025 * | 1.26 x |
P/E ratio 2024 * |
25.2
x | P/E ratio 2025 * |
15.7
x | Employees | - |
Yield 2024 * |
2.22% | Yield 2025 * |
2.97% | Free-Float | 69.3% |
Latest transcript on IPD Group Limited
1 day | +2.21% | ||
1 week | +0.22% | ||
Current month | +0.87% | ||
1 month | +3.12% | ||
3 months | -3.14% | ||
6 months | +19.69% | ||
Current year | -4.15% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 14-12-31 | |
Jason Boschetti
DFI | Director of Finance/CFO | - | 22-11-27 |
Mohamed Yoosuff
PRN | Corporate Officer/Principal | - | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Moffat
BRD | Director/Board Member | 62 | 20-03-23 |
David Rafter
CHM | Chairman | - | 19-08-13 |
Chief Executive Officer | - | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 4.62 | +2.21% | 58,069 |
24-05-02 | 4.52 | -0.66% | 52,432 |
24-05-01 | 4.55 | -0.66% | 71,062 |
24-04-30 | 4.58 | -1.29% | 108,819 |
24-04-29 | 4.64 | +0.65% | 97,875 |
Delayed Quote Australian S.E., May 03, 2024 at 02:10 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.15% | 306M | |
-3.55% | 8.39B | |
+5.17% | 8.05B | |
+14.71% | 7.08B | |
+6.03% | 1.31B | |
+88.18% | 800M | |
-10.45% | 638M | |
+65.43% | 613M | |
-1.69% | 601M | |
+134.53% | 518M |
- Stock Market
- Equities
- IPG Stock